CN102793683B - 一种含左旋米那普仑的缓释组合物及其制备方法 - Google Patents
一种含左旋米那普仑的缓释组合物及其制备方法 Download PDFInfo
- Publication number
- CN102793683B CN102793683B CN 201210323131 CN201210323131A CN102793683B CN 102793683 B CN102793683 B CN 102793683B CN 201210323131 CN201210323131 CN 201210323131 CN 201210323131 A CN201210323131 A CN 201210323131A CN 102793683 B CN102793683 B CN 102793683B
- Authority
- CN
- China
- Prior art keywords
- release
- acrylic resin
- hypromellose
- composition
- handed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 229960000685 levomilnacipran Drugs 0.000 title abstract 4
- 239000004925 Acrylic resin Substances 0.000 claims abstract description 46
- 229920000178 Acrylic resin Polymers 0.000 claims abstract description 46
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 45
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 45
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 43
- 239000000463 material Substances 0.000 claims abstract description 22
- 238000013268 sustained release Methods 0.000 claims abstract description 12
- 239000012730 sustained-release form Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 229960000600 milnacipran Drugs 0.000 claims description 64
- 229960003943 hypromellose Drugs 0.000 claims description 31
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 15
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 15
- 239000003002 pH adjusting agent Substances 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 239000000945 filler Substances 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 10
- 229950005770 hyprolose Drugs 0.000 claims description 10
- 239000003232 water-soluble binding agent Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000010409 thin film Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 238000009501 film coating Methods 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 238000005550 wet granulation Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000012530 fluid Substances 0.000 abstract description 34
- 230000000968 intestinal effect Effects 0.000 abstract description 27
- 230000002496 gastric effect Effects 0.000 abstract description 18
- 230000006399 behavior Effects 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract description 12
- 239000004480 active ingredient Substances 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 78
- 238000000034 method Methods 0.000 description 42
- 239000008363 phosphate buffer Substances 0.000 description 41
- 239000003814 drug Substances 0.000 description 40
- 239000008187 granular material Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 23
- 238000002156 mixing Methods 0.000 description 23
- 239000003826 tablet Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 17
- 238000001035 drying Methods 0.000 description 12
- 238000005469 granulation Methods 0.000 description 11
- 230000003179 granulation Effects 0.000 description 11
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 238000011978 dissolution method Methods 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- 238000005070 sampling Methods 0.000 description 9
- 210000004051 gastric juice Anatomy 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 235000021355 Stearic acid Nutrition 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- -1 hydroxypropyl Chemical group 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229920003091 Methocel™ Polymers 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 239000013563 matrix tablet Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 229920003105 Methocel™ A15 LV Polymers 0.000 description 1
- XNCDYJFPRPDERF-PBCQUBLHSA-N Milnacipran hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1C[NH3+] XNCDYJFPRPDERF-PBCQUBLHSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229960000638 milnacipran hydrochloride Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210323131 CN102793683B (zh) | 2012-09-04 | 2012-09-04 | 一种含左旋米那普仑的缓释组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210323131 CN102793683B (zh) | 2012-09-04 | 2012-09-04 | 一种含左旋米那普仑的缓释组合物及其制备方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310061815.6A Division CN103083274B (zh) | 2012-09-04 | 2012-09-04 | 一种含左旋米那普仑的缓释组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102793683A CN102793683A (zh) | 2012-11-28 |
CN102793683B true CN102793683B (zh) | 2013-04-17 |
Family
ID=47193155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210323131 Active CN102793683B (zh) | 2012-09-04 | 2012-09-04 | 一种含左旋米那普仑的缓释组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102793683B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1232387A (zh) * | 1996-08-28 | 1999-10-20 | 皮埃尔法博赫药品公司 | 延长释放米那普仑的盖伦制剂 |
US20090018203A1 (en) * | 2002-10-25 | 2009-01-15 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
WO2011107921A2 (en) * | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Modified release composition of milnacipran |
-
2012
- 2012-09-04 CN CN 201210323131 patent/CN102793683B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1232387A (zh) * | 1996-08-28 | 1999-10-20 | 皮埃尔法博赫药品公司 | 延长释放米那普仑的盖伦制剂 |
US20090018203A1 (en) * | 2002-10-25 | 2009-01-15 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
WO2011107921A2 (en) * | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Modified release composition of milnacipran |
Also Published As
Publication number | Publication date |
---|---|
CN102793683A (zh) | 2012-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK165939B (da) | Metropololpraeparat med styret, kontinuerlig afgivelse af det aktive stof, farmaceutisk praeparat indeholdende samme og fremgangsmaade til fremstilling af metropololpraeparatet samt anvendelse af metropololpraeparatet til fremstilling af et farmaceutisk praeparat til behandling af kardiovaskulaere lidelser | |
KR20130083903A (ko) | 저장 안정성 제제를 제조하기 위한 결합제의 용도 | |
RU2013125148A (ru) | Пероральная фармацевтическая таблетка с регулируемым высвобождением месалазина и способ ее получения | |
CN102438597A (zh) | 一种选自中枢性作用肌弛缓药类型的化合物的新型缓释制剂 | |
US20030224045A1 (en) | Combination immediate release sustained release levodopa/carbidopa dosage forms | |
JP2011241218A (ja) | pH非依存延長放出性医薬組成物 | |
CN110420192B (zh) | 一种单硝酸异山梨酯缓释片及制备方法 | |
CN104814923B (zh) | 一种盐酸坦洛新缓释制剂及其制备方法和其应用 | |
CN101204387A (zh) | 一种盐酸坦洛新缓释胶囊 | |
CN105012264B (zh) | 丙戊酸钠缓释片及其制备工艺和用途 | |
CN103520169A (zh) | 米氮平片及其制备方法 | |
WO2011072481A1 (zh) | 一种颗粒组合控释片 | |
SK50442006A3 (sk) | Pelety obsahujúce hydrochlorid venlafaxínu | |
CN102793683B (zh) | 一种含左旋米那普仑的缓释组合物及其制备方法 | |
CN103083274B (zh) | 一种含左旋米那普仑的缓释组合物及其制备方法 | |
CN107412198A (zh) | 盐酸度洛西汀肠溶缓释颗粒剂及其制备方法 | |
KR101587140B1 (ko) | 위장관 질환 치료용 모사프리드 구연산염 미니정제 함유 서방성 캡슐 제제 및 이의 제조 방법 | |
CN1248693C (zh) | 复方氨基葡萄糖盐缓释制剂及其制备方法 | |
CN102283816B (zh) | 西洛多辛缓释片剂及其制备方法 | |
CN102836135B (zh) | 一种阿司匹林肠溶片及其制备工艺 | |
JP6854162B2 (ja) | 錠剤 | |
CN101711753B (zh) | 兰索拉唑固体制剂的制备方法 | |
CN102525989B (zh) | 洛索洛芬钠骨架缓释片 | |
JP2018508501A (ja) | タムスロシン塩酸塩含有徐放性顆粒を含む経口用薬剤学的製剤 | |
CN104840442B (zh) | 一种含有富马酸喹硫平的缓释片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ge Yabo Inventor after: Mo Zhimin Inventor after: Fu Wuzhong Inventor after: Wang Yan Inventor after: Chen Tiane Inventor before: Ge Yabo |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: GE YABO TO: GE YABO MO ZHIMIN FU WUZHONG WANG YAN CHEN TIANE |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 33, Xiaxian 1st Village, Meilan District, Haikou City, Hainan Province Patentee after: Hainan Qirong Information Technology Co.,Ltd. Address before: Xiuying District East Ocean Road 570311 Hainan city of Haikou province No. 4 standard factory building three layer Patentee before: HAINAN KANGHONG MEDICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Slow-release composition containing L-milnacipran and preparation method thereof Effective date of registration: 20200528 Granted publication date: 20130417 Pledgee: China Everbright Bank Co.,Ltd. Haikou Branch Pledgor: Hainan Qirong Information Technology Co.,Ltd. Registration number: Y2020980002573 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210701 Granted publication date: 20130417 Pledgee: China Everbright Bank Co.,Ltd. Haikou Branch Pledgor: Hainan Qirong Information Technology Co.,Ltd. Registration number: Y2020980002573 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a sustained-release composition containing l-minapram and a preparation method thereof Effective date of registration: 20210705 Granted publication date: 20130417 Pledgee: China Everbright Bank Co.,Ltd. Haikou Branch Pledgor: Hainan Qirong Information Technology Co.,Ltd. Registration number: Y2021980005697 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230329 Address after: Room 1506, Building B, Jinghai Garden, No. 1, Haidian Island Sandong Road, Haidian Street, Meilan District, Haikou City, Hainan Province, 570100 Patentee after: Ge Yabo Address before: No. 33, Xiaxianyi Village, Meilan District, Haikou City, Hainan Province, 570100 Patentee before: Hainan Qirong Information Technology Co.,Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230608 Granted publication date: 20130417 Pledgee: China Everbright Bank Co.,Ltd. Haikou Branch Pledgor: Hainan Qirong Information Technology Co.,Ltd. Registration number: Y2021980005697 |